A Long-term, Multi-center, Longitudinal Post-marketing, Observational Registry to Assess Long Term Safety and Effectiveness of HUMIRA® (Adalimumab) in Children With Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis (JIA) - STRIVE

Trial Profile

A Long-term, Multi-center, Longitudinal Post-marketing, Observational Registry to Assess Long Term Safety and Effectiveness of HUMIRA® (Adalimumab) in Children With Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis (JIA) - STRIVE

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Adalimumab (Primary) ; Methotrexate
  • Indications Juvenile rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms STRIVE
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 17 Jun 2017 Seven year interim analysis results (n=838; as of 1 Jun 2016) presented at the 18th Annual Congress of the European League Against Rheumatism
    • 02 Jun 2016 Results will be presented at the Annual European Congress of Rheumatology (EULAR 2016), as reported by AbbVie media release.
    • 13 Jun 2015 Interim results presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top